The latest World Health Organization’s (WHO) Pandemic Agreement falls short of protecting all countries in future pandemics, said international patient groups and public health organizations.
Researchers from State University of New Jersey (Rutgers) and Oklahoma State University have published preclinical data for a novel a SARS-CoV-2 papain-like protease (PLpro) inhibitor being developed as an antiviral candidate for the treatment of COVID-19.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amgen, Apellis, Avistone, Biogen, Bristol Myers Squibb, Gilead, Hutchmed, Johnson & Johnson, Novartis, Pfizer, Ractigen, Sobi, Takeda.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Allogene, Biosenic, Biovie, Immunoengineering, Moderna, Mosaic Immunoengineering, Oncotelic, Signalchem, Sino Biological.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aligos, Arbele, Biocardia, Caliway, Can-Fite, Nkgen, Recce.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abeona, Astrazeneca, Averoa, Beigene, Edgewise, Immunitybio, Innocan, Medivir, Oncoc4, Revive, Tiziana.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Asklepios, Bayer, Imunon and Lumicell.
In a study from the PHOSP-COVID and ISARIC-4C consortia in the U.K., researchers have discovered inflammatory processes taking place during what is termed “long COVID.” Long COVID is defined by the World Health Organization (WHO) as the continuation or development of new symptoms for 3 or more months after the initial SARS-CoV-2 infection. It is estimated that 1 in 10 SARS-CoV-2 infections results in long COVID, thus affecting about 65 million people worldwide.
SARS-CoV-2 could proliferate in the lungs causing severe COVID-19 through a special type of immune cell. A group of scientists from Stanford University observed how this coronavirus infected interstitial macrophages through a CD209 receptor, triggering the inflammatory response observed in hospitalized patients.
Researchers at Schrodinger Inc. and Takeda Pharmaceutical Co. Ltd. have described 3C-like proteinase (3CLpro; Mpro; nsp5) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome.
RSS
